Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study

O'Shaughnessy, J.Cicin, I.Testa, L.Tolaney, S. M.Huober, J.Guarneri, V.Johnston, S. R. D.2024-06-122024-06-1220230923-75341569-8041https://doi.org/10.1016/j.annonc.2023.09.471https://hdl.handle.net/20.500.14551/25588Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- OCT 20-24, 2023 -- Barcelona, SPAIN[Abstract Not Available]en10.1016/j.annonc.2023.09.471info:eu-repo/semantics/openAccess[No Keywords]Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE studyConference Object34S293S293N/AWOS:001087480200266